Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.46
IPXL's Cash to Debt is ranked lower than
74% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. IPXL: 0.46 )
Ranked among companies with meaningful Cash to Debt only.
IPXL' s 10-Year Cash to Debt Range
Min: 0.39  Med: 9999.00 Max: No Debt
Current: 0.46
Equity to Asset 0.49
IPXL's Equity to Asset is ranked lower than
70% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. IPXL: 0.49 )
Ranked among companies with meaningful Equity to Asset only.
IPXL' s 10-Year Equity to Asset Range
Min: 0.2  Med: 0.54 Max: 0.84
Current: 0.49
0.2
0.84
Interest Coverage 2065.49
IPXL's Interest Coverage is ranked lower than
51% of the 390 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2854.00 vs. IPXL: 2065.49 )
Ranked among companies with meaningful Interest Coverage only.
IPXL' s 10-Year Interest Coverage Range
Min: 1.51  Med: 460.35 Max: 9999.99
Current: 2065.49
1.51
9999.99
F-Score: 3
Z-Score: 2.76
M-Score: -1.23
WACC vs ROIC
10.06%
2.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 5.86
IPXL's Operating margin (%) is ranked lower than
55% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. IPXL: 5.86 )
Ranked among companies with meaningful Operating margin (%) only.
IPXL' s 10-Year Operating margin (%) Range
Min: -1418.74  Med: 0.31 Max: 44.72
Current: 5.86
-1418.74
44.72
Net-margin (%) 1.19
IPXL's Net-margin (%) is ranked lower than
68% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. IPXL: 1.19 )
Ranked among companies with meaningful Net-margin (%) only.
IPXL' s 10-Year Net-margin (%) Range
Min: -1376.35  Med: 9.26 Max: 46
Current: 1.19
-1376.35
46
ROE (%) 0.85
IPXL's ROE (%) is ranked lower than
68% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. IPXL: 0.85 )
Ranked among companies with meaningful ROE (%) only.
IPXL' s 10-Year ROE (%) Range
Min: -341.31  Med: 6.76 Max: 125.75
Current: 0.85
-341.31
125.75
ROA (%) 0.54
IPXL's ROA (%) is ranked lower than
66% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. IPXL: 0.54 )
Ranked among companies with meaningful ROA (%) only.
IPXL' s 10-Year ROA (%) Range
Min: -70.9  Med: 3.63 Max: 38.8
Current: 0.54
-70.9
38.8
ROC (Joel Greenblatt) (%) 5.98
IPXL's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. IPXL: 5.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IPXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -297.18  Med: 27.58 Max: 236.29
Current: 5.98
-297.18
236.29
Revenue Growth (3Y)(%) 3.50
IPXL's Revenue Growth (3Y)(%) is ranked lower than
59% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. IPXL: 3.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IPXL' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 44.20 Max: 203.4
Current: 3.5
0
203.4
EBITDA Growth (3Y)(%) 1.60
IPXL's EBITDA Growth (3Y)(%) is ranked lower than
57% of the 494 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. IPXL: 1.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IPXL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -14.95 Max: 61.6
Current: 1.6
0
61.6
EPS Growth (3Y)(%) -5.80
IPXL's EPS Growth (3Y)(%) is ranked lower than
64% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IPXL: -5.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IPXL' s 10-Year EPS Growth (3Y)(%) Range
Min: -32.2  Med: -6.05 Max: 55.1
Current: -5.8
-32.2
55.1
» IPXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

IPXL Guru Trades in Q3 2014

Joel Greenblatt 33,709 sh (New)
Jim Simons 39,400 sh (New)
Paul Tudor Jones 36,853 sh (+104.74%)
NWQ Managers 1,298,995 sh (+31.90%)
RS Investment Management 809,959 sh (-13.92%)
John Hussman 250,000 sh (-19.35%)
» More
Q4 2014

IPXL Guru Trades in Q4 2014

Alan Fournier 533,100 sh (New)
Mario Gabelli 6,775 sh (New)
Joel Greenblatt 79,609 sh (+136.17%)
Jim Simons 61,400 sh (+55.84%)
Paul Tudor Jones 39,050 sh (+5.96%)
John Hussman 250,000 sh (unchged)
RS Investment Management Sold Out
NWQ Managers 906,043 sh (-30.25%)
» More
Q1 2015

IPXL Guru Trades in Q1 2015

George Soros 61,206 sh (New)
Alan Fournier 2,025,000 sh (+279.85%)
Jim Simons 71,900 sh (+17.10%)
NWQ Managers 936,127 sh (+3.32%)
John Hussman 250,000 sh (unchged)
Joel Greenblatt Sold Out
Mario Gabelli Sold Out
Paul Tudor Jones 9,300 sh (-76.18%)
» More
Q2 2015

IPXL Guru Trades in Q2 2015

Chase Coleman 430,000 sh (New)
Steven Cohen 183,000 sh (New)
Alan Fournier 3,204,096 sh (+58.23%)
George Soros Sold Out
Paul Tudor Jones 9,000 sh (-3.23%)
John Hussman 200,000 sh (-20.00%)
NWQ Managers 710,302 sh (-24.12%)
Jim Simons 14,100 sh (-80.39%)
» More
» Details

Insider Trades

Latest Guru Trades with IPXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 400.87
IPXL's P/E(ttm) is ranked lower than
98% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.60 vs. IPXL: 400.87 )
Ranked among companies with meaningful P/E(ttm) only.
IPXL' s 10-Year P/E(ttm) Range
Min: 4.04  Med: 47.90 Max: 1043
Current: 400.87
4.04
1043
Forward P/E 18.32
IPXL's Forward P/E is ranked higher than
60% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.47 vs. IPXL: 18.32 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 415.70
IPXL's PE(NRI) is ranked lower than
99% of the 478 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. IPXL: 415.70 )
Ranked among companies with meaningful PE(NRI) only.
IPXL' s 10-Year PE(NRI) Range
Min: 4.04  Med: 47.69 Max: 1043
Current: 415.7
4.04
1043
P/B 2.99
IPXL's P/B is ranked higher than
50% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. IPXL: 2.99 )
Ranked among companies with meaningful P/B only.
IPXL' s 10-Year P/B Range
Min: 1.32  Med: 2.97 Max: 12.8
Current: 2.99
1.32
12.8
P/S 4.43
IPXL's P/S is ranked lower than
63% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. IPXL: 4.43 )
Ranked among companies with meaningful P/S only.
IPXL' s 10-Year P/S Range
Min: 1.17  Med: 3.15 Max: 12.72
Current: 4.43
1.17
12.72
EV-to-EBIT 136.48
IPXL's EV-to-EBIT is ranked lower than
94% of the 491 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.81 vs. IPXL: 136.48 )
Ranked among companies with meaningful EV-to-EBIT only.
IPXL' s 10-Year EV-to-EBIT Range
Min: -642.3  Med: 34.00 Max: 216.9
Current: 136.48
-642.3
216.9
Shiller P/E 25.67
IPXL's Shiller P/E is ranked higher than
64% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.72 vs. IPXL: 25.67 )
Ranked among companies with meaningful Shiller P/E only.
IPXL' s 10-Year Shiller P/E Range
Min: 10.23  Med: 19.94 Max: 61.99
Current: 25.67
10.23
61.99
Current Ratio 3.10
IPXL's Current Ratio is ranked higher than
63% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. IPXL: 3.10 )
Ranked among companies with meaningful Current Ratio only.
IPXL' s 10-Year Current Ratio Range
Min: 1.12  Med: 3.47 Max: 10.65
Current: 3.1
1.12
10.65
Quick Ratio 2.56
IPXL's Quick Ratio is ranked higher than
66% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. IPXL: 2.56 )
Ranked among companies with meaningful Quick Ratio only.
IPXL' s 10-Year Quick Ratio Range
Min: 0.63  Med: 2.99 Max: 10.07
Current: 2.56
0.63
10.07
Days Inventory 101.40
IPXL's Days Inventory is ranked higher than
56% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.99 vs. IPXL: 101.40 )
Ranked among companies with meaningful Days Inventory only.
IPXL' s 10-Year Days Inventory Range
Min: 50.25  Med: 96.02 Max: 398.94
Current: 101.4
50.25
398.94
Days Sales Outstanding 136.47
IPXL's Days Sales Outstanding is ranked lower than
83% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. IPXL: 136.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPXL' s 10-Year Days Sales Outstanding Range
Min: 34.05  Med: 85.17 Max: 1169.47
Current: 136.47
34.05
1169.47

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 32.71
IPXL's Price/Tangible Book is ranked lower than
96% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. IPXL: 32.71 )
Ranked among companies with meaningful Price/Tangible Book only.
IPXL' s 10-Year Price/Tangible Book Range
Min: 1.45  Med: 3.24 Max: 36.74
Current: 32.71
1.45
36.74
Price/Projected FCF 2.84
IPXL's Price/Projected FCF is ranked lower than
53% of the 319 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.70 vs. IPXL: 2.84 )
Ranked among companies with meaningful Price/Projected FCF only.
IPXL' s 10-Year Price/Projected FCF Range
Min: 1  Med: 1.71 Max: 3.82
Current: 2.84
1
3.82
Price/Median PS Value 1.41
IPXL's Price/Median PS Value is ranked lower than
61% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. IPXL: 1.41 )
Ranked among companies with meaningful Price/Median PS Value only.
IPXL' s 10-Year Price/Median PS Value Range
Min: 0.42  Med: 1.21 Max: 26.88
Current: 1.41
0.42
26.88
Price/Graham Number 23.50
IPXL's Price/Graham Number is ranked lower than
99% of the 360 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. IPXL: 23.50 )
Ranked among companies with meaningful Price/Graham Number only.
IPXL' s 10-Year Price/Graham Number Range
Min: 0.68  Med: 1.46 Max: 31.77
Current: 23.5
0.68
31.77
Earnings Yield (Greenblatt) (%) 0.69
IPXL's Earnings Yield (Greenblatt) (%) is ranked lower than
65% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. IPXL: 0.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IPXL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.5  Med: 2.20 Max: 55.9
Current: 0.69
0.5
55.9
Forward Rate of Return (Yacktman) (%) -22.16
IPXL's Forward Rate of Return (Yacktman) (%) is ranked lower than
91% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.88 vs. IPXL: -22.16 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
IPXL' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -22.2  Med: 0.90 Max: 144.8
Current: -22.16
-22.2
144.8

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 800 922 1,013 1,143
EPS($) 1.32 2.25 2.82 3.85
EPS without NRI($) 1.32 2.25 2.82 3.85

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:ILR.Germany,
Impax Laboratories Inc is a Delaware corporation was incorporated in 1995. It is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products, commonly referred to as 'generics' in addition to the development and marketing of branded products. The Company operates in two segments namely Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Division develops, manufactures, sells and distributes its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. The Company develops, manufacture, sell and distribute specialty generic pharmaceuticals. The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products mainly through four sales channels: the 'Global products' sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, large retail drug chains, and others; the 'Private Label' sales channel, for generic pharmaceutical over-the-counter ('OTC') and prescription products the Company sells to unrelated third-party customers who in-turn sell the product to third parties under its own label; the 'Rx Partner' sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements; and the 'OTC Partner' sales channel, for sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements. The Impax Division is engaged in the development of proprietary brand pharmaceutical products. The Impax Division is also engaged in the sale and distribution of branded Zomig(r) (zolmitriptan) products, indicated for the treatment of migraine headaches, under the terms of a Distribution, License, Development and Supply Agreement (AZ Agreement) with AstraZeneca UK Limited (AstraZeneca). The Company's Impax Division develops proprietary brand pharmaceutical products through improvements to already approved pharmaceutical products to address central nervous system ('CNS') disorders. The Impax Division is also engaged in the co-promotion through a direct sales force focused on marketing to physicians, mainly in the CNS community, pharmaceutical products developed by other unrelated third-party pharmaceutical entities. The Company markets and sells its generic pharmaceutical prescription drug products within the continental United States of America and the Commonwealth of Puerto Rico. The chemical raw materials, essential to its business, are generally readily available from multiple sources in the U.S. and throughout the world. Generic pharmaceutical product develop
» More Articles for IPXL

Headlines

Articles On GuruFocus.com
Alan Fournier's Highest Performing Stocks Jul 15 2015 
Alan Fournier's Most Heavily Weighted Trades In Q1 2015 May 28 2015 
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
comment on IPXL Sep 24 2012 
President and CEO of Impax Laboratories Inc. (IPXL) Larry Hsu Bought 10,000 Shares Aug 17 2011 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 5,000 Shares Aug 12 2010 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 10,000 Shares Aug 12 2010 
Impax Laboratories Reports Second Quarter 2009 Financial Results Aug 04 2009 

More From Other Websites
Major Insider Activity Spotted At Inovalon Holdings Inc. (INOV), Impax Laboratories Inc. (IPXL), and... Aug 28 2015
IMPAX LABORATORIES INC Financials Aug 20 2015
10-Q for Impax Laboratories, Inc. Aug 12 2015
5 Biotechs Leerink Analysts Are Watching Aug 11 2015
Apple (AAPL) Holding Slashed By Giovine Capital But Remains Fund’s Top Pick For Q3 Aug 11 2015
Edited Transcript of IPXL earnings conference call or presentation 10-Aug-15 12:30pm GMT Aug 10 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation... Aug 10 2015
Q2 2015 Impax Laboratories Inc Earnings Release - After Market Close Aug 10 2015
Impax Labs reports 2Q loss Aug 10 2015
Impax Labs reports 2Q loss Aug 10 2015
Impax Reports Second Quarter 2015 Financial Results Aug 10 2015
Impax Announces Sale of Daraprim® to Turing Pharmaceuticals AG Aug 10 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Aug 05 2015
Hikma Pharmaceuticals Plc: Strong price momentum but will it sustain? Jul 29 2015
Coverage initiated on Impax Labs by Susquehanna Jul 21 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Jul 08 2015
Impax to Report Second Quarter 2015 Results on August 10, 2015 Jul 06 2015
Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors Jul 06 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination... Jun 30 2015
Alan Fournier Sells Stake in Gilead Sciences Jun 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK